Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Subscribe To Our Newsletter & Stay Updated